Ocuphire Pharma, Inc.

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

SEE WHO WE ARE

CORPORATE PRESENTATION

A Clear-sighted Product Pipeline

Nyxol®

Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances

Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Nyxol

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Our Clinical Trials

Ocuphire Pharma plans to readout 4 clinical trials with a potential NDA filing for the RM indication in 2022.

View Clinical Trials

Latest News

Ocuphire Announces Upcoming Presentations at European Forum 2022, [email protected] 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

Ocuphire Pharma Receives PDUFA Fee Waiver for Nyxol New Drug Application from FDA

View Release

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

View Release

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

View Release

Stock Snapshot

View Investor Relations